In my opinion, investors may want to consider the three stocks that are listed in this article, since they could meet the following value criteria:
- These stocks do not seem expensive, as their price-earnings ratios are 20 or less
- Their earnings and revenue, both on a per share basis, have advanced over the past five years, while no losses had to be noted in the years in question
- These stocks have positive recommendation ratings from sell-side analysts on Wall Street.
JPMorgan Chase & Co
The first stock to consider is JPMorgan Chase & Co (JPM, Financial), a U.S. bank major.
The company saw its trailing 12-month revenue per share increase by 7.8% and its trailing 12-month earnings per share (EPS) without non-recurring items (NRI) increase by 14.6% over the past five years.
The price-earnings ratio (15.90 as of Tuesday) increased by a 4% average growth rate over the period in question.
The stock traded at around $121.67 per share at close on Tuesday for a market cap of $370.87 billion and a dividend yield of 2.96%.
GuruFocus assigned a financial strength rating of 3 out of 10 and a profitability rating of 5 out of 10 to the company.
Wall Street sell-side analysts recommend a median rating of overweight for this stock and have established an average target price of $125.79 per share.
UnitedHealth Group Inc
The second stock to consider is UnitedHealth Group Inc (UNH, Financial), a Minnetonka, Minnesota-based diversified healthcare company.
The company saw its trailing 12-month revenue per share increase by 13.1% and its trailing 12-month EPS without NRI increase by 22.6% every year over the past five years.
The price-earnings ratio (19.24 as of Tuesday) has declined by 0.4% over the period in question.
The stock was trading at around $335.01 per share at close on Tuesday for a market cap of $317.86 billion and a dividend yield of 1.46%.
GuruFocus assigned a score of 6 out of 10 to the company's financial strength rating and of 9 out of 10 to its profitability rating.
Wall Street sell-side analysts recommend a median rating of overweight for this stock and have established an average target price of $388.12 per share.
Meridian Bioscience Inc
The third stock to consider is Meridian Bioscience Inc (VIVO, Financial), a Cincinnati, Ohio-based developer and distributor of test kits to diagnose several infectious diseases and abnormal levels of lead in the blood.
The company saw its trailing 12-month revenue per share increase by 3.7% and its trailing 12-month EPS without NRI increase by 1.1% per year over the past five years.
The price-earnings ratio (19.50 as of Tuesday) has decreased over the observed period at an average rate of 1.7%.
The stock traded at around $21.06 per share at close on Tuesday for a market capitalization of $908.17 million.
Meridian Bioscience has not paid any dividends in 2020.
GuruFocus assigned the company a score of 7 out of 10 for its financial strength rating and of 8 out of 10 for the profitability rating.
Wall Street sell-side analysts recommend a median rating of buy for this stock and have established an average target price of $26.67 per share.
Disclosure: I have no positions in any securities mentioned.
Read more here:
- 3 Long-Term Payers Announce Dividends
- A Trio of Stock Picks for the Value Investor
- 3 Stocks Growing Earnings Fast
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
